Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 52-week results of the ESTEEM 2 Trial

被引：0
|
作者：
Paul, C. [1 ]
Gooderham, M. [2 ]
Cather, J. [3 ]
Poulin, Y. [4 ]
Girolomoni, G. [5 ]
Ferrandiz, C. [6 ]
Gottlieb, A. B. [7 ]
Mrowietz, U. [8 ]
Hu, Cc. [9 ]
Day, R. M. [9 ]
Richter, S. [10 ]
Crowley, J. [11 ]
机构：
[1] Toulouse Univ, Hop Larrey, Toulouse, France
[2] SKiN Ctr Dermatol, Peterborough, ON, Canada
[3] Modern Res Associates, Dallas, TX USA
[4] Ctr Rech Dermatol Quebec Metropolitain, Quebec City, PQ, Canada
[5] Univ Verona, I-37100 Verona, Italy
[6] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[7] Tufts Med Ctr, Boston, MA USA
[8] Univ Hosp Schleswig Holstein, Kiel, Germany
[9] Celgene Corp, Warren, NJ USA
[10] Celgene Corp, Melbourne, Vic, Australia
[11] Bakersfield Dermatol, Bakersfield, CA USA
来源：
AUSTRALASIAN JOURNAL OF DERMATOLOGY | 2015年 / 56卷
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
引用
收藏
页码：63 / 63
页数：1
相关论文
共 50 条
  • [1] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with nail, scalp, and palmoplantar psoriasis: 52-week ESTEEM 2 study results
    Crowley, J.
    Gooderham, M.
    Wasel, N.
    Weisman, J.
    Tyring, S.
    Hu, C. C.
    Day, R. M.
    Richter, S.
    Ferrandiz, C.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2015, 56 : 63 - 63
  • [2] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with nail, scalp, and palmoplantar psoriasis: 52-week results from the ESTEEM 2 study
    Crowley, Jeffrey
    Gooderham, Melinda
    Wasel, Norman
    Weisman, Jamie
    Tyring, Stephen
    Hu, ChiaChi
    Day, Robert
    Ferrandiz, Carlos
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB226 - AB226
  • [3] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with nail, scalp and palmoplantar psoriasis: 52-Week results from the ESTEEM 2 study
    Gooderham, Melinda
    Crowley, Jeffrey
    Wasel, Norman
    Weisman, Jamie
    Tyrings, Stephen
    Hu, ChiaChi
    Day, Robert
    Ferrandiz, Carlos
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2015, 135 : S31 - S31
  • [4] Apremilast, an oral phosphodiesterase 4 inhibitor, in nail and scalp psoriasis: 52-week results from the ESTEEM 1 study
    Foley, P.
    Papp, K.
    Reich, K.
    Leonardi, C.
    Kircik, L.
    Chimenti, S.
    Rich, P.
    Hu, C. C.
    Stevens, R. M.
    Day, R. M.
    Griffiths, C. E. M.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2014, 55 : 34 - 35
  • [5] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase 3, randomized, controlled trial (ESTEEM 2)
    Paul, Carle
    Crowley, Jeffrey
    Cather, Jennifer
    Gooderham, Melinda
    Day, Robert
    Mrowietz, Ulrich
    Poulin, Yves
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2014, 70 (05) : AB164 - AB164
  • [6] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: 16-week results of a phase III, randomized, controlled trial (esteem 1)
    Reich, K.
    Papp, K.
    Leonardi, C.
    Kircik, L.
    Chimenti, S.
    Hu, C.
    Stevens, R.
    Day, R. M.
    Griffiths, C. E.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2013, 27 : 22 - 23
  • [7] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: Pruritus and DLQI correlations at week 16 (ESTEEM 1 and 2)
    Feldman, Steven R.
    Thaci, Diamant
    Ling, Mark
    Gooderham, Melinda
    Chi, Chia
    Day, Robert M.
    Goodfield, Mark
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB226 - AB226
  • [8] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe psoriasis: ESTEEM 1 randomized treatment withdrawal phase results
    Foley, P.
    Papp, K.
    Reich, K.
    Leonardi, C.
    Kircik, L.
    Chimenti, S.
    Hu, C. C.
    Stevens, R. M.
    Day, R. M.
    Griffiths, C. E. M.
    AUSTRALASIAN JOURNAL OF DERMATOLOGY, 2014, 55 : 35 - 35
  • [9] Efficacy and Safety of Apremilast and Switch from Etanercept in Patients with Moderate to Severe Psoriasis: 52-Week Results
    Reich, Kristian
    Soung, Jennifer
    Gooderham, Melinda
    Zhang, Zuoshun
    Nograles, Kristine
    Day, Robert M.
    Ferris, Laura
    Goodfield, Mark
    ARTHRITIS & RHEUMATOLOGY, 2016, 68
  • [10] Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with moderate to severe plaque psoriasis: Pooled 16-week efficacy in patient subgroups (ESTEEM 1 and 2)
    Korman, Neil
    Poulin, Yves
    Griffiths, Christopher
    Chimenti, Sergio
    Sofen, Howard
    Philipp, Sandra
    Hu, ChiaChi
    Day, Robert
    Girolomoni, Giampiero
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2015, 72 (05) : AB225 - AB225
12345